We use cookies to make it easier for you to use our website and give you a better experience. We aggregate the information we get through cookies from users like you, and analyze that data to better understand user behavior and help us improve the website. We do not give or sell the data you provide through cookies to any third party for any purpose (such as advertising or marketing). By using this website, you consent to Organogenesis using cookies for these purposes. You may change your settings anytime by clicking on the “Security” tab on your browser. Note that Organogenesis is located in the United States, and the U.S. has not yet been determined to have “adequate” data privacy safeguards by the EU; despite any inherent risks in the transfer of data from the EU, Organogenesis takes the security of your information seriously. To read our privacy policy, click here.
What is Apligraf®?How Apligraf® WorksHow Apligraf® Works

The Science Behind Apligraf®

A unique living-cell based product available to treat non-healing wounds
For patients with diabetic foot ulcers or venous leg ulcers, Apligraf® is an advanced living treatment providing hope for healing some of the most persistent non-healing ulcers.

(More... )

Clinical Experience

A history of healing
Apligraf® was developed and is manufactured by Organogenesis, one of the world’s first regenerative medicine companies, and the world’s most important tissue regeneration company. Apligraf® has been used worldwide to heal ulcers for over 10 years. Apligraf® is the first living, cell-based tissue regeneration product, having gained the Food and Drug Administration’s approval in 1998.

(More... )


3. Falanga V, Sabolinski ML. A bilayered living skin construct (Apligraf®) accelerates complete closure of hard-to-heal venous ulcers. Wound Repair Regen. 1999;7:201-207.

4. Veves A, Falanga V, et al. Graftskin, a human skin equivalent, is effective in management of non-infected neuropathic diabetic foot ulcers. Diabetes Care. 2001;24:290-295